India Cell And Gene Therapy Cdmo Market Size & Outlook
Related Markets
India cell and gene therapy cdmo market highlights
- The India cell and gene therapy cdmo market generated a revenue of USD 115.4 million in 2024 and is expected to reach USD 823.3 million by 2033.
- The India market is expected to grow at a CAGR of 24.8% from 2025 to 2033.
- In terms of segment, pre-clinical was the largest revenue generating phase in 2024.
- Pre-clinical is the most lucrative phase segment registering the fastest growth during the forecast period.
Cell and gene therapy cdmo market data book summary
| Market revenue in 2024 | USD 115.4 million |
| Market revenue in 2033 | USD 823.3 million |
| Growth rate | 24.8% (CAGR from 2025 to 2033) |
| Largest segment | Pre-clinical |
| Fastest growing segment | Pre-clinical |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pre-clinical, Clinical |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
Other key industry trends
- In terms of revenue, India accounted for 2.7% of the global cell and gene therapy cdmo market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China cell and gene therapy cdmo market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 823.3 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell And Gene Therapy CDMO Market Scope
Cell And Gene Therapy CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Cytiva | View profile | 10001+ | Marlborough, Massachusetts, United States, North America | https://www.cytivalifesciences.com/en/us |
| Rentschler Biopharma SE | View profile | 501-1000 | Laupheim, Baden-Wurttemberg, Germany, Europe | https://www.rentschler-biopharma.com |
| Catalent Inc | View profile | 17219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | https://www.catalent.com |
| AGC Inc | View profile | 61671 | 1-5-1, Marunouchi, Chiyoda-ku, Tokyo, Japan, 100-8405 | https://www.agc.com |
| Wuxi AppTec Co Ltd | View profile | 41116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | https://www.wuxiapptec.com |
| OmniAb Inc | View profile | 106 | 5980 Horton Street, Suite 600, Emeryville, CA, United States, 94608 | https://www.omniab.com |
| Charles River Laboratories International Inc | View profile | 21400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | https://www.criver.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Samsung Electronics Co Ltd | View profile | 124804 | 129, Samsung-ro, Yeongtong-gu, Gyeonggi-do, Suwon-si, Korea, Republic of, 443-742 | https://www.samsung.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
India cell and gene therapy cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 78.86% in 2024. Horizon Databook has segmented the India cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2021 to 2033.
India is expected to emerge as one of the lucrative markets for pharmaceutical CDMOs across the globe. This can be attributed to low costs, the availability of industry experts, and the presence of WHOcGMP-compliant facilities.
In addition, some of the key players in India providing CDMO services are Wuxi AppTec; Charles River Laboratories International, Inc.; IQVIA; Recipharm AB; and Catalent, Inc. Local players include Dr. Reddy’s Laboratories, Cadila Healthcare Limited, and Cipla Ltd. Several CMOs & CROs operating in India have expanded their facilities to meet the growing demand for pharmaceuticals.
Moreover, leading players are actively seeking to expand their customer base, production capacities, and market presence. For instance, in October 2023, a new formulations manufacturing facility was commissioned by Aragen, a leading provider of contract research, development, and manufacturing services for pharmaceutical & biotechnology industries, in Hyderabad, India.
Reasons to subscribe to India cell and gene therapy cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of India cell and gene therapy cdmo market databook
-
Our clientele includes a mix of cell and gene therapy cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the India cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into India cell and gene therapy cdmo market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
India cell and gene therapy cdmo market size, by phase, 2021-2033 (US$M)
India Cell And Gene Therapy CDMO Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
